Mounjaro vs Wegovy: UK Provider and Cost Comparison
Compare Wegovy and Mounjaro for UK readers by treatment difference, dose pathway, price context, side effects and access.
Wegovy vs Mounjaro in the UK usually comes down to four practical questions: what the difference is, what each treatment tends to cost, how access works, and where to check live provider detail next. This guide keeps the comparison practical and UK-specific.
What matters first
Wegovy contains semaglutide. Mounjaro contains tirzepatide. Both are prescription-only weekly injections, but they are not interchangeable and they are not usually priced in exactly the same way.
The clearest way to compare them is to start with the medicine itself, then move on to dose progression, provider pricing and access. Jumping straight to the lowest-looking number can mean comparing two different stages of treatment.
Different medicines
Both are weekly injections, but semaglutide and tirzepatide are not the same treatment.
Different pricing patterns
The amount you pay can change a lot once dose stage, delivery fees and provider extras come into view.
Different access picture
Private providers, NHS eligibility and follow-up support all matter alongside the medicine itself.
Wegovy vs Mounjaro: the short version
| Comparison point | Wegovy | Mounjaro |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| How it is taken | Once-weekly injection | Once-weekly injection |
| Dose pathway | Usually increased gradually towards a 2.4mg maintenance dose, depending on assessment and tolerability | Usually starts at 2.5mg and can step up in 2.5mg stages to 15mg, depending on assessment and tolerability |
| What usually differs between providers | Starting dose price, maintenance pricing, delivery fees, follow-up and how clearly the treatment is explained | Starting dose price, later higher-dose pricing, delivery fees, follow-up and how clearly the treatment is explained |
| What changes the real price | There is no one fixed answer. The real comparison depends on the dose being shown, what is included, whether delivery is separate and what happens after the first order. | |
| NHS position | Criteria-led and tied to service availability rather than broad public demand | Also criteria-led and service-dependent rather than a routine open-access option |
| Side-effect conversation | Often centres on gastrointestinal side effects, dose increases and day-to-day tolerability | Also often centres on gastrointestinal side effects, dose increases and day-to-day tolerability |
| Useful next page | See current Wegovy providers | See current Mounjaro providers |
The short answer
They are not the same treatment
Wegovy and Mounjaro are both weekly injections, but they use different active ingredients and have different dose pathways.
The lowest-looking number may mislead
A starting price rarely tells the whole story. Dose stage, delivery charges and provider extras can change the total quite a lot.
Private comparison is easier to check
Private provider pages are usually the fastest place to compare live pricing, delivery detail and follow-up support.
NHS access is more limited
Both medicines have NICE guidance, but NHS access is narrower and depends on eligibility and local service availability.
How the price comparison actually works
“Wegovy vs Mounjaro price” sounds like it should have one simple answer. In practice, providers do not always show prices in the same way. One page may highlight the starting dose. Another may make the later dose stages look clearer. Some include delivery in the headline figure. Others leave it out.
So the better question is not simply “which one is cheaper?” It is:
Which dose is being shown?
A low starting-dose price and a later maintenance-stage price are not the same thing. Compare like with like.
What is included?
Check whether delivery, support or review is built into the headline figure or charged separately.
How recent is the information?
Pricing and service details can move. A recently reviewed page is more useful than an older page with a tidy-looking number.
What happens after the first order?
The first-stage price may not tell you much about the longer treatment cost if the dose rises later.
For live provider detail rather than one number taken out of context, these are the pages worth opening next:
Compare current Wegovy provider pages Compare current Mounjaro provider pages Review wider treatment cost comparison
How the dose pathway differs
Wegovy and Mounjaro are both weekly injections, but the dose pathway is not the same. That affects not only how the treatment is explained, but also how later-stage pricing tends to look.
Wegovy treatment
Wegovy is the semaglutide option. UK label information and NICE guidance frame it as a weekly treatment used alongside wider weight-management measures. In practice, comparisons often focus on the starting stage, the move toward 2.4mg maintenance and how clearly providers explain the treatment over time.
Mounjaro treatment
Mounjaro is the tirzepatide option. UK label information describes a weekly injection that usually begins at 2.5mg and may step up in 2.5mg stages depending on assessment and tolerability. In practice, comparisons often become more important as treatment moves through higher-dose stages and provider price gaps widen.
If you are deciding between them, this is one of the most important practical differences to understand early. Two treatments can look similar at the start and then feel quite different once dose changes, follow-up and later-stage pricing come into view.
“Which is better?” is not just a weight-loss question
Many people searching this topic want one simple answer. In real life, the comparison is usually more personal than that. Both treatments are often discussed in relation to gastrointestinal side effects, dose increases and day-to-day tolerability, and neither should be treated like a casual shopping decision.
The better way to think about it is to keep four things in view:
- regulated prescribing and eligibility checks
- side-effect discussion and tolerability
- ongoing review, support and continuity
- the difference between the medicine itself and the way a provider manages treatment
For general UK safety context around GLP-1 medicines and regulated supply, see the MHRA consumer guidance.
Private access is easier to compare, but NHS access matters too
Most people first come across these medicines through private provider pages, because that is where the pricing and treatment information is easiest to find. That still does not make either one a simple consumer purchase. Both remain prescription-only and both need a regulated prescriber decision.
Private providers
This is usually the fastest place to make progress, because pricing, delivery detail and follow-up information are visible in one place.
NHS access
NICE guidance exists for both medicines, but access is narrower and depends on service delivery, local pathways and eligibility rather than open consumer choice.
Eligibility
Weight, BMI, comorbidity context, medical history and prescribing judgment matter more than any broad claim about the right option.
Provider checks
Look for clear prescribing information, realistic follow-up detail, transparent pricing and signs that the provider is handling treatment responsibly.
What to read next
Wegovy providers
Open this if semaglutide still looks like the option you want to explore in more detail.
See Wegovy providersMounjaro providers
Open this if you want the current tirzepatide provider picture, including higher-dose price movement.
See Mounjaro providersInjection comparison hub
Open this if you are still comparing weekly injection treatments more broadly rather than narrowing down to one medicine now.
Compare injectionsCost guide
Open this if your biggest concern is how to read treatment costs without getting pulled in by a headline price.
Review cost guideWegovy vs Mounjaro UK: common questions
Is Wegovy or Mounjaro cheaper in the UK?
There is no single permanent answer. It depends on the dose stage shown, the provider, delivery charges, support model and how the treatment changes over time.
Is Mounjaro stronger than Wegovy?
That is not a safe one-line answer. The medicines use different active ingredients and suitability depends on clinical assessment, tolerability and prescribing context rather than hype.
Are both available privately in the UK?
Private provider comparison is the easiest place to start online, but both still require regulated prescribing checks and should only be approached through legitimate UK providers.
Are both available on the NHS?
Both have NICE guidance in overweight and obesity, but NHS access is narrower and service-dependent. Search demand should not be confused with routine open access.
Can you switch from Wegovy to Mounjaro or the other way round?
Switching is a clinical and provider-process question, not something to assume from a comparison article alone. If that is your situation, compare provider handover and review information carefully.
Is Ozempic the same as Wegovy?
No. They both contain semaglutide, but they are not the same consumer comparison. If that distinction matters to your search, see our Ozempic, Wegovy and Rybelsus explainer.
Medical and UK guidance checked for this page
This page was reviewed against current UK guidance and label sources on 23 May 2026. Those sources are used for medicine, access and safety context. Live provider pricing and service details sit on the dedicated treatment and provider pages, where they can be checked more often.
Source checks
Wegovy Prescribing Information
The Wegovy Summary of Product Characteristics was reviewed for medicine identity and prescribing-information context.
Checked: 27 April 2026 Confidence: High
Source: eMC: Wegovy 2.4mg FlexTouch SmPC
Reviewed for identification-only context. Readers should use patient information and clinician guidance for personal questions.
Mounjaro Prescribing Information
The Mounjaro Summary of Product Characteristics was reviewed for medicine identity and prescribing-information context.
Checked: 27 April 2026 Confidence: High
Source: eMC: Mounjaro KwikPen 2.5mg SmPC
Reviewed for identification-only context. Readers should use patient information and clinician guidance for personal questions.
Head To Head Trial Context
A published head-to-head obesity trial was reviewed only to describe trial-level evidence, not individual suitability.
Checked: 27 April 2026 Confidence: High
Source: PubMed: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
Reviewed to explain the 72-week adults-with-obesity comparison background and why trial averages should not be treated as personal advice.
Safety And Prescription Context
GOV.UK/MHRA patient information was reviewed for GLP-1 medicine safety and prescription-only context.
Checked: 27 April 2026 Confidence: High
Source: GOV.UK: GLP-1 medicines for weight loss and diabetes
Reviewed for cautious language around assessment, side effects and regulated supply.
NICE Semaglutide Guidance
NICE guidance was reviewed for UK semaglutide access context. This is not personal eligibility advice.
Checked: 27 April 2026 Confidence: High
Source: NICE TA875: semaglutide for managing overweight and obesity
Reviewed for UK access and background on the Wegovy side of the comparison.
NICE Tirzepatide Guidance
NICE guidance was reviewed for UK tirzepatide access context. This is not personal eligibility advice.
Checked: 27 April 2026 Confidence: High
Source: NICE TA1026: tirzepatide for managing overweight and obesity
Reviewed for UK access and background on the Mounjaro side of the comparison.
Important information
This website is an informational comparison hub. It does not prescribe, supply or sell prescription-only medicines. Suitability depends on a regulated clinical assessment.
Some links may be affiliate or commercial links. Commercial relationships must not change the way safety, eligibility, source checks or editorial context are presented.